US FDA’s Stein ‘Excited’ About Real-World Evidence, Rare Disease Endpoint Pilot Programs
Executive Summary
Head of Office of New Drugs highlights programs being established under PDUFA VII that could help overcome obstacles in drug development.
You may also be interested in...
US FDA Solicits Comments On Barriers To Innovative Trial Design Implementation
In admitting problems, the FDA creates a docket for comments and will convene a public workshop in the spring on why the clinical trial innovation is not more widespread.
New Translational Science Team Created In US FDA’s CDER To Aid Rare Disease Drug Development
The group is intended to help rare disease drug developers answer all the necessary questions about surrogate endpoints and markers before the application review cycle.
Real-World Evidence: US FDA Urged To Leverage Prior Validation Work and Regulatory Experience
In comments on FDA guidance on electronic health records and medical claims, Duke-Margolis Center suggests a certification process for validated datasets, while data companies request the agency do more to publicize the experience to date with RWE in regulatory submissions.